Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 1,500 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $149.12, for a total transaction of $223,680.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of NASDAQ:JAZZ opened at $150.06 on Wednesday. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56. The firm has a market cap of $8.46 billion, a P/E ratio of 12.26, a P/E/G ratio of 0.94 and a beta of 1.15. Jazz Pharmaceuticals PLC has a 12 month low of $113.52 and a 12 month high of $153.03. The company’s 50-day moving average price is $137.19 and its two-hundred day moving average price is $133.22.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The company had revenue of $537.70 million during the quarter, compared to the consensus estimate of $523.92 million. During the same period in the previous year, the firm posted $3.58 earnings per share. The company’s revenue was up 14.6% on a year-over-year basis. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 14.15 earnings per share for the current fiscal year.
Several research analysts recently issued reports on the stock. TheStreet raised shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, November 29th. Wells Fargo & Co lifted their price objective on Jazz Pharmaceuticals from $168.00 to $186.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Piper Jaffray Companies downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $205.00 to $142.00 in a report on Wednesday, August 21st. Evercore ISI reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, November 11th. Finally, BidaskClub upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $168.71.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: How to Use the New Google Finance Tool
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.